Navigation Links
Patient-derived stem cells could improve drug research for Parkinson's
Date:7/4/2012

Researchers have taken a step toward personalized medicine for Parkinson's disease, by investigating signs of the disease in patient-derived cells and testing how the cells respond to drug treatments. The study was funded by the National Institutes of Health.

The researchers collected skin cells from patients with genetically inherited forms of Parkinson's and reprogrammed those cells into neurons. They found that neurons derived from individuals with distinct types of Parkinson's showed common signs of distress and vulnerability in particular, abnormalities in the cellular energy factories known as mitochondria. At the same time, the cells' responses to different treatments depended on the type of Parkinson's each patient had.

The results were published in Science Translational Medicine.

"These findings suggest new opportunities for clinical trials of Parkinson's disease, in which cell reprogramming technology could be used to identify the patients most likely to respond to a particular intervention," said Margaret Sutherland, Ph.D., a program director at NIH's National Institute of Neurological Disorders and Stroke (NINDS).

A consortium of researchers conducted the study with primary funding from NINDS. The consortium is led by Ole Isacson, M.D., Ph.D., a professor of neurology at McLean Hospital and Harvard Medical School in Boston.

The NINDS consortium's first goal was to transform the patients' skin cells into induced pluripotent stem (iPS) cells, which are adult cells that have been reprogrammed to behave like embryonic stem cells. The consortium researchers then used a combination of growth conditions and growth-stimulating molecules to coax these iPS cells into becoming neurons, including the type that die in Parkinson's disease.

Parkinson's disease affects a number of brain regions, including a motor control area of the brain called the substantia nigra. There, it destroys neurons that
'/>"/>

Contact: Daniel Stimson, NINDS
nindspressteam@ninds.nih.gov
301-496-5751
NIH/National Institute of Neurological Disorders and Stroke
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Tumor microenvironment helps skin cancer cells resist drug treatment
2. Study results: Adult stem cells from bone marrow
3. Amniotic fluid yields alternatives to embryonic stem cells
4. Myelodysplastic syndromes (MDS) linked to abnormal stem cells
5. Short stretches of piRNA evaluate cells genetic history
6. Regulation of telomerase in stem cells and cancer cells
7. Blood-brain barrier building blocks forged from human stem cells
8. Bringing down the cost of fuel cells
9. Cells to Civilizations: The Principles of Change That Shape Life
10. Research could help track stem cells in the body
11. New method generates cardiac muscle patches from stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
(Date:7/23/2014)... and blood-brain barrier damage appear after cerebral ... Matrix metalloproteinase-9 is able to degrade the ... cerebral blood vessels and to mediate extracellular ... colleagues from the First Affiliated Hospital of ... induced cerebral infarction in stroke-prone spontaneously hypertensive ...
(Date:7/23/2014)... Scientists with the NH Agricultural Experiment Station are working ... after new research based on genetic monitoring has found ... New England have become more isolated and seen a ... endangered New England cottontail is now is at risk ... Agricultural Experiment Station researchers at the University of New ...
Breaking Biology News(10 mins):Nano-sized chip "sniffs out" explosives far better than trained dogs 2UNH NHAES researchers work to save endangered New England cottontail 2UNH NHAES researchers work to save endangered New England cottontail 3
... The ubiquitous and usually harmless E. coli bacterium, which ... has more than 1,000 of them involved in metabolism ... genes would theoretically be capable of generating a huge ... report in the Dec. 27 issue of Proceedings of ...
... medical doctor. Yet he is seen as a hero by ... was diagnosed with terminal lung cancer. , "In 2000 he ... months to live," said Pardini, a professor of biochemistry and ... University of Nevada, Reno. "But five years later, he ...
... great challenges for treating Parkinson's diseases and other neurodegenerative disorders ... , The brain is a complex organ with many different ... a protective barrier erected by blood vessels and glial cells ... the delivery of most drugs from the bloodstream. , But ...
Cached Biology News:How E. coli bacterium generates simplicity from complexity 2How E. coli bacterium generates simplicity from complexity 3The nude mouse tale: Omega-3 fats save the life of a terminal cancer patient 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 3
(Date:7/23/2014)... TEL AVIV, Israel , July 23, 2014 ... Ltd ., a portfolio company of Trendlines ... with one of Israel,s ... (Logo: http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines ... from plant pulp waste, with additional nanoparticles to ...
(Date:7/23/2014)... , July 23, 2014 regulated information -- UCB ... and development pipeline with positive topline results from ... . This study was designed to evaluate the efficacy ... 200 mg/day, without titration) compared to placebo, as ... partial-onset seizures, not fully controlled despite treatment with ...
(Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
(Date:7/23/2014)... July 23, 2014 OncLive® is ... Center has joined its Strategic Alliance Partnership program. ... Partnership program, UNC Lineberger will have the opportunity ... awareness of its cutting-edge research initiatives, community-directed cancer ... Lineberger will work with OncLive to educate their ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... , CORALVILLE, Iowa, Nov. 17 Vivakor, Inc. (OTC ... approved a dividend of shares of common stock of HealthAmerica, ... of the outstanding common stock. Each Vivakor shareholder will ... for each share of Vivakor common stock beneficially owned on ...
... Neuralstem, Inc. (NYSE Amex: CUR ) today provided a financial ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO ) , ... loss of $5,096,983, or $0.15 per share, compared with a net ... period. The increase was due to a non-cash charge related to ...
... LEIDEN, The Netherlands, November 17 ... with Actelion Pharmaceuticals Ltd,Erasmus Medical Centre and Maastricht ... hypertension (high blood pressure) and associated vascular,complications such as ... novel action mechanisms, new drugs may be discovered with,the ...
Cached Biology Technology:Vivakor, Inc. Announces Stock Dividend 2Vivakor, Inc. Announces Stock Dividend 3Vivakor, Inc. Announces Stock Dividend 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 2Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 5Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 6Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 7New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications 2
... are rigid macroporous hydrophilic media. The rigid ... moderate pressures, while the macroporous beads enhance ... matrix reduces nonspecific binding. Macro-Prep High Q ... with very high flow rates and resolution. ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... The IDS 25-Hydroxy Vitamin D kit ... quantitative determination of 25-hydroxyvitamin D (25-OH ... human serum or plasma. Our patented ... of solvent precipitation and centrifugation and ...
... A multi-purpose, high gel-strength agarose suitable for ... from conventional constant field to Pulsed Field ... gel strength and exclusion limits, Multi ABgarose ... reduced running times. This in turn means ...
Biology Products: